Cara Therapeutics Inc., of Shelton, Conn., disclosed the dosing of the first dialysis patients in a phase II trial of an intravenous formulation of its peripherally selective kappa opioid agonist, CR845, for the treatment of uremic pruritus. The company expects to report top-line data from this trial in the first half of 2015.